Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net revenue:
Total net revenues	$ 5,687	$ 3,809
Cost of goods sold	2,484	1,517
Gross margin	3,203	2,292
Operating expenses:
Research and development	1,539	1,002
Depreciation and amortization	163	218
Selling, general and administrative	4,517	3,298
Total operating expenses	6,219	4,518
Loss from operations	(3,016)	(2,226)
Loss on extinguishment of debt	(199)
Interest expense	(172)	(302)
Interest income	4	4
Other expense, net	(35)	(74)
Loss before income taxes	(3,418)	(2,598)
Income tax benefit	93	1,789
Net loss	(3,325)	(809)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(77)
Net loss attributable to Nephros, Inc.	(3,402)	(809)
Other comprehensive income (loss), foreign currency translation adjustments, net of tax	(6)	10
Total comprehensive loss attributable to Nephros, Inc.	$ (3,408)	$ (799)
Net loss per common share, basic and diluted	$ (0.06)	$ (0.02)
Weighted average common shares outstanding, basic and diluted	61,620,423	52,935,728
Product Revenue [Member]
Net revenue:
Total net revenues	$ 5,457	$ 3,544
License, Royalty and Other Revenues [Member]
Net revenue:
Total net revenues	$ 230	$ 265